17:00 Mon 06 Jul 2020
IXICO plc - Grant of share options
("IXICO" or the "Company")
Grant of share options
The 450,000 options awarded are split:
i) 300,000 options issued to members of the Company's Senior Leadership Team (the 'SLT Options'); and
ii) 150,000 options issued to other employees within the Company (the 'Employee Options').
The SLT Options are subject to performance conditions linked to revenue and share price accretion across three years.
The Employee Options are subject to performance conditions linked to profitability and retention within the Company across three years.
For further information please contact:
|
+44 (0)20 3763 7498 |
|||
|
|
|||
|
|
|||
Cenkos Securities PLC (Nominated adviser and sole broker) |
+44 (0)20 7397 8900 |
|||
|
|
|||
Michael F Johnson / |
|
|||
|
|
|||
|
Tel: 020 7933 8780 or IXICO@walbrookpr.com |
|||
|
Mob: 07980 541 893 / 07584 391 303 / |
|||
|
07407 804 654 |
|||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE